Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fecal Microbiota Transplantation in Patients With Acute Gastrointestinal Graft-versus-host-disease
NCT03819803Phase 3Recruiting
- Sponsor
- Medical University of Graz
- Start
- Mar 2017
- Primary completion
- Mar 2027
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of allogeneic fecal microbiota in graft-versus-host disease (GVHD), sponsored by Medical University of Graz. Primary endpoint: Gastrointestinal Acute Graft-versus-host-disease Remission at 90 days. Started Mar 2017; status: recruiting.
02
Drugs
allogeneic fecal microbiota
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT03819803.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03819803.